Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, April 2001, p. 1058-1064, Vol. 45, No. 4
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.4.1058-1064.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Peptide Deformylase as an Antibacterial Drug
Target: Target Validation and Resistance Development
Christian M.
Apfel,*
Hans
Locher,
Stefan
Evers,
Béla
Takács,
Christian
Hubschwerlen,
Wolfgang
Pirson,
Malcolm G. P.
Page, and
Wolfgang
Keck
Pharma Research Basel, F. Hoffmann-La Roche
Ltd., CH-4070 Basel, Switzerland
Received 10 August 2000/Returned for modification 5 October
2000/Accepted 20 December 2000
 |
ABSTRACT |
New inhibitors of peptide deformylase (PDF) which are very potent
against the isolated enzyme and show a certain degree of antibacterial
activity have recently been synthesized by our group. Several lines of
experimental evidence indicate that these inhibitors indeed interfere
with the target enzyme in the bacterial cell. (i) The inhibition of
Escherichia coli growth could be counteracted by
overexpression of PDF from different organisms, including E. coli, Streptococcus pneumoniae, and Haemophilus
influenzae. Conversely, reduced expression of PDF in S. pneumoniae resulted in an increased susceptibility to the
inhibitors. (ii) Proteome analysis on two-dimensional gels revealed a
shift for many proteins towards lower pI in the presence of PDF
inhibitors, as would be expected if the proteins still carry their
N-formyl-Met terminus. (iii) PDF inhibitors show no
antimicrobial activity against E. coli under conditions that make growth independent of formylation and deformylation. The
antibacterial activity in E. coli was characterized as
bacteriostatic. Furthermore, the development of resistance in E. coli was observed to occur with high frequency
(10
7). Resistant mutants show a reduced growth rate, and
DNA sequence analysis revealed mutations in their formyl transferase
gene. Taking all these aspects into account, we conclude that PDF may not be an optimal target for broad-spectrum antibacterial agents.
 |
INTRODUCTION |
Antibiotic resistance is a major
health concern, and the existing antibiotics target only a handful of
molecules. Therefore, there is an urgent need for antibiotics with
novel mechanisms of action. Peptide deformylase (PDF; EC 3.5.1.27) is
essential in a variety of pathogenic bacteria but is not required for
cytoplasmic protein synthesis in eukaryotes and is therefore an
interesting potential target for antibacterial agents. Protein
synthesis in eubacteria, under normal conditions, is initiated by
formyl-methionyl-tRNA (19). Consequently, all
nascent polypeptides are synthesized with
N-formyl-methionine at the N terminus. The formyl
group is removed by PDF during elongation of the polypeptide chain
(1, 7). As methionine aminopeptidase (EC 3.4.11.18) cannot
hydrolyze N-blocked polypeptides, deformylation is also a prerequisite
for protein maturation (10, 22, 27). Both PDF and MAP, are
essential for growth in Escherichia coli (10, 19,
21). pdf gene mutants can only be obtained in
E. coli strains lacking the gene for formyltransferase, the
enzyme that N-formylates the methionyl-tRNA
(EC.2.1.2.9) (20).
In a recent publication, we described the identification, optimization,
and biological characterization of novel PDF inhibitors (3). These compounds were potent inhibitors of the
isolated enzyme but only moderately active as antibacterials. In the
accompanying paper, we describe transcription-translation assays that
allowed us to demonstrate that the inhibitors were active as inhibitors of PDF in cell homogenates as well as in intact cells
(4a). The experimental evidence presented here
demonstrates that (i) antibacterial activity of the compounds results
from PDF inhibition, (ii) the inhibitors lead to impaired deformylation
of multiple proteins, (iii) the inhibitors are bacteriostatic, and (iv)
the development of resistance is relatively rapid. In light of these results and other findings, we discuss the potential of PDF as an
antibacterial target.
 |
MATERIALS AND METHODS |
Bacterial strains, plasmids, enzymes, and chemicals.
The
E. coli strains used in this study were XL2-blue and BL21
(DE3) carrying pLysS (Stratagene, Basel, Switzerland) and DC2 from our
own strain collection. The strains were grown in Luria-Bertani medium
(Difco Laboratories, Detroit, Mich.) with aeration at 37°C. Streptococcus pneumoniae R6 (6) was routinely
grown on sheep blood (3%) agar plates, and liquid cultures were
propagated in Todd-Hewitt broth (Difco Laboratories) and incubated with
10% CO2 at 37°C. Haemophilus influenzae ATCC
51907 was grown in minimal medium (8) with a reduced
methionine concentration (0.6 µM). The plasmids pET-3a and pET-28a
were from Novagen (Abington, United Kingdom). Restriction enzymes were
from New England Biolabs (Beverly, Mass.) or Amersham Pharmacia Biotech
(Dübendorf, Switzerland) and were used in accordance with the
specifications of the manufacturer. All other chemicals, including
actinonin (Ro 06-1467), were from Sigma (St. Louis, Mo.). The synthesis
of Ro 66-0376 and Ro 66-6976 is described elsewhere (3)
(Fig. 1).
Determination of the MICs.
The MICs of the test compounds
were determined by broth microdilution. The MIC of a compound was
defined as the lowest concentration that prevented visible growth of
bacteria after incubation at 37°C for 24 h, or 72 h for
slow-growing strains. Iso-Sensitest broth (Oxoid, Basingstoke, United
Kingdom) was used as the test medium.
Time-kill assay.
For time-kill studies, glass tubes
containing 7 ml of Iso-Sensites broth were inoculated with
approximately 5 × 107 CFU of an exponentially growing
culture of E. coli DC2/ml. The concentration of the
antibiotics was 32 µg/ml, i.e., approximately eight times the MIC.
The cultures were incubated at 37°C in a shaking water bath, and
viability counts were performed at different time points by plating
appropriate dilutions on Trypticase soy agar (Difco). Colony counts
were recorded after incubation at 37°C for 24 h.
General DNA techniques and transformation.
Chromosomal DNA
preparation was performed using the Qiagen (Hilden, Germany) genomic
DNA purification system. Preparation of plasmid DNA was performed using
the Promega (Madison, Wis.) Wizard mini- or maxipurification system.
Plasmids, PCR products, and chromosomal DNA were cleaved with the
appropriate restriction enzymes, ligated, and transformed into E. coli XL2 blue cells (5, 24). Transformants were
selected on Luria-Bertani agar plates containing ampicillin (100 µg/ml) for pET-3a and pDS56
cat, kanamycin (20 µg/ml) for
pET-28a, or erythromycin (500 µg/ml) for pJDC9 and its derivatives.
Transformation of S. pneumoniae was performed as described
by Havarstein et al. (14) with modifications. Briefly,
frozen aliquots of competent cells were thawed, diluted 10-fold with
prewarmed medium (16), and incubated for 20 min at 37°C
in an atmosphere of 10% CO2. One microliter of plasmid DNA
(1 µg/µl) was added to 500 µl of the mixture, and incubation continued for an additional 3 h. Transformants were selected on sheep blood (3%) agar plates containing erythromycin (0.5 µg/ml). Competent cells were obtained by growing R6 in Todd-Hewitt medium, supplemented with 5% calf serum, to an optical density at 660 nm
(OD660) of 0.3 to 0.5. The culture was diluted (1/10),
glycerol was added to a final concentration of 10%, and aliquots were
flash frozen at
80°C.
PCR and sequencing.
PCR was performed with the Expand
High-Fidelity DNA system (Roche Diagnostics, Rotkreuz, Switzerland)
according to the manufacturer's recommendations in a Perkin-Elmer
(Foster City, Calif.) thermocycler. Sequencing was performed using the
dideoxy chain termination method (26) with a modified DNA
sequencing kit (dye terminator cycle sequencing; PE Applied Biosystems,
Foster City, Calif.) and an automated DNA sequencing system (ABI Prism
310 genetic analyzer; PE Applied Biosystems). Nucleotide and amino acid
sequences were analyzed with the University of Wisconsin Genetics
Computer Group sequence analysis package (13) and with the
Lasergene program (DNASTAR, Madison, Wis.).
Construction of expression plasmids for PDF.
The
pdf genes from E. coli (EMBL accession no.
ecdeff), H. influenzae (EMBL accession no., hi32745), and
S. pneumoniae (EMBL accession no., spn278785) were expressed
in an IPTG (ispropyl-
-D-thiogalactopyranoside)-inducible system (Fig. 2A). In all cases,
full-length genes were PCR amplified using the appropriate forward and
reverse primers. The selected forward primer introduced a
BsaI site (5'-GGTCTCTCATG-3') for H. influenzae or an NdeI site (5'-GCCATATG-3')
for E. coli and S. pneumoniae overlapping
with the start codon. The reverse primer introduced a BamHI
site for E. coli and H. influenzae and an
EcoRI site for S. pneumoniae downstream from the
stop codon. The PCR products were digested with the corresponding
restriction enzymes, isolated from an agarose gel, and cloned into
pET-3a for the E. coli and S. pneumoniae genes
and into pET-28a for H. influenzae, resulting in pPDF-EC,
pPDF-SP, and pPDF-HI (Fig. 2A). The correctness of the PCR inserts was
verified by DNA sequencing. Both pET-3a and pET-28a carry T7 promoters
and are designed to allow protein expression via activation of T7
polymerase synthesis by IPTG in an appropriate E. coli
strain, such as BL21, which carries the T7 polymerase gene under the
control of the lacUV5 promoter (29). The T7
promoter carried by pET-28a contains an additional binding site for the
lac repressor.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 2.
Plasmids used in this study. (A) Plasmids used for
controlled expression of pdf genes from E. coli, H. influenzae, and S. pneumoniae. (B) Plasmids for
generating controlled pdf gene disruptions in S. pneumoniae. A small internal fragment of the gene was cloned into
pJDC9, resulting in pKO1. An amino-terminal fragment of the
pdf gene was cloned into the insertion vectors pRKO5 and
pRKO6, resulting in plasmids pKO2 and pKO3, which allow
tetracycline-regulated pdf expression in the transformants.
For details, see Material and Methods. The numbers indicate the
nucleotides, starting with 1 at the putative initiation codon of each
gene. Abbreviations for restriction enzymes: Ba, BamHI; Bs,
BsaI; Ec, EcoRI; Kp, KpnI; Nc,
NcoI; Nd, NdeI; Ps, PstI.
|
|
Construction of plasmids for generating PDF gene
disruptions.
A small (381-bp) fragment internal to the
pdf gene from S. pneumoniae (nucleotides 87 to
467) was amplified by PCR for use in disrupting the pdf gene
and terminating expression of the downstream genes in the operon. The
forward primer used introduced an EcoRI site, and the
reverse primer introduced a PstI site. The PCR product was
cloned into pJDC9 (EcoRI-PstI) (12),
resulting in pKO1 (Fig. 2B). As a positive control for gene disruption
experiments, pJDC9 carrying a DNA fragment internal to the nonessential
amiC gene was used (2). In order to introduce
two different tetracycline-regulatable promoters into the promoter
region of the pdf operon, an N-terminal fragment of the
pdf gene (nucleotides 1 to 269) was amplified by PCR. The
forward primer introduced a BsaI site
(5'-GGTCTCTCATG-3') upstream from the start codon, and the
reverse primer introduced a KpnI site. The digested PCR
product was cloned into vectors pRKO5 and pRKO6
(NcoI-KpnI), resulting in plasmids pKO2 and pKO3 (Fig. 2B). The vectors pRKO5 and pRKO6 are derivatives of pRKO1 and -2, respectively. The last plasmids were designed for insertional gene
inactivation and introduce a Tet operator upstream from the start codon
of the targeted gene (4, 28). The plasmids pRKO5 and -6 are improved derivatives of these vectors that allow the use of the
authentic start codons for expression studies (M. Stieger, unpublished
data). Recombinants were propagated in E. coli XL2. Mutants
were generated in S. pneumoniae R6 by transformation using the protocol described above. The authenticity of each clone was confirmed by sequencing.
2D polyacrylamide gel electrophoresis (PAGE).
H.
influenzae cultures were grown under aeration (200 rpm) to an
OD600 of 0.4. The compounds Ro 66-0376 and actinonin were added to final concentrations of 32 and 16 µg/ml, respectively. After
incubation for 30 and 90 min, the cultures were pulse-labeled with 20 µCi of L-[35S]methionine (20 fmol), rapidly
chilled on ice, and harvested by centrifugation at 15,000 × g. In parallel, an untreated control culture was labeled
correspondingly. The bacterial pellets were washed once in a solution
containing 10 mM Tris-HCl (pH 8.0) 1 mM EDTA, and 7% (wt/vol) glucose
and resuspended in lysis solution containing 8 M urea, 4% (wt/vol)
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 40 mM Tris base, 65 mM 1,4-dithioerythritol, and 2% (vol/vol) ampholytes
Resolyte, pH 6 to 9.5 (BDH, Poole, United Kingdom). Soluble extracts
were prepared by centrifugation of the lysate at 100,000 × g for 1 h at 10°C. The incorporated radioactivity was
determined by scintillation counting. An aliquot of the protein solution (4 × 106 cpm) was loaded onto Immobiline
3-10 nonlinear pH gradient (IPG) strips (Pharmacia, Uppsala, Sweden) at
the basic end and resolved according to the manufacturer's
recommendations. After isoelectric focusing, the strips were
equilibrated as described previously (25), and
electrophoresis was carried out on 1-mm-thick 20- by 25-cm 12%
polyacrylamide slab gels. The gels were dried, and the images were
acquired on a PhosphorImager device (Molecular Dynamics, Sunnyvale,
Calif.). The protein identities and pI values were tentatively assigned
by comparison with an H. influenzae reference
two-dimensional (2D) map (17). The pI estimations were
based on the IPG strip manufacturer's specifications and on the
theoretical pI values of reference proteins.
 |
RESULTS |
Overexpression of PDF counteracts the growth inhibition in E. coli caused by PDF inhibitor Ro 66-0376.
The PDF proteins
from different species (E. coli, H. influenzae, and S. pneumoniae) were overexpressed in E. coli. The level of
expression was regulated by the level of inducer added (0, 0.04, and
0.1 mM IPTG) (Fig. 3). For the E. coli and S. pneumoniae enzymes, we could show an
induction level-dependent decrease of susceptibility to
the PDF inhibitor (Ro 66-0376) treatment. For the H. influenzae PDF, this effect was less pronounced. Induction of
either the S. pneumoniae or the E. coli enzyme
with an IPTG concentration of 1 mM was lethal for the host bacteria.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 3.
Counteracting effect of overexpressing PDF from
different species on growth inhibition by Ro 66-0376. E. coli BL21 transformed with the indicated plasmids was grown to an
OD578 of 0.05 and distributed into 96-well plates.
Increasing amounts of IPTG (as indicated) were used to induce the
expression of the PDFs, and increasing amounts of the inhibitor Ro
66-0376 were added. The OD595 was measured after 5 h
of incubation. The E. coli strain harboring vector pET-3a is
shown as the control (noninduced). Conc., concentration.
|
|
Construction and analysis of regulatable pdf gene
disruptions in S. pneumoniae.
Knockout mutants were
constructed in S. pneumoniae by site-directed insertional
mutagenesis (23) to investigate the function of the
pdf gene. A small internal gene fragment was cloned into the
plasmid pJDC9, which does not replicate in pneumococci. The construct
(pKO1 [Fig. 2B]) was transformed into S. pneumoniae R6 and
plasmid-encoded erythromycin resistance (Emr) was used to
select for single homologous recombination events. No Emr
transformants were obtained in several repeated experiments, suggesting
that pdf is essential in S. pneumoniae.
To further study the role of the
pdf gene in bacterial
growth, we used a regulatable knockout system that allows conditional
gene expression (Fig.
4). Regulation of
gene expression by using
the TetR and TetO regulatory elements had been
shown to be extremely
efficient (
18). Therefore, the
potential promoter region upstream
from the streptococcal
pdf gene was replaced by two different
tetracycline-regulatable promoters: (i) p57 in pKO2 (weak promoter;
relatively tight) and (ii) p57opt in pKO3 (p57optimal; stronger
promoter and higher basal expression level then p57) (
28).
Transforming
S. pneumoniae R6 with these plasmids resulted
in erythromycin-resistant
transformants in the presence and absence of
tetracycline. Contrary
to our expectations, we could not observe any
difference between
the growth rates of cultures grown in the presence
and in the
absence of tetracycline (data not shown; several independent
transformants
were tested), indicating that the basal transcription
level from
these promoters, even p57, was sufficient to allow normal
growth
of the transformants.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 4.
Schematic representation of the chromosomal
pdf mutants of S. pneumoniae R6 with
integrational plasmids. The numbers indicate the nucleotides, starting
with 1 at the initiation codon of each gene. P1 to P4 indicate the
primers used in the PCR to prove the correct integration of the
plasmids. regul., regulatable.
|
|
A decrease in pdf expression in S. pneumoniae enhances the growth inhibition caused by PDF inhibitor
Ro 66-0376.
The degrees of inhibition of bacterial growth by Ro
66-0376 in S. pneumoniae R6 and the conditional knockout
mutant S. pneumoniae KO3 (Fig. 4) were compared. For strain
R6, as expected, no difference in growth rate was detected between
tetracycline-induced cultures and control cultures: the 50% inhibitory
concentration was around 13 µM (Fig.
5). Strain KO3 exhibited a higher
susceptibility to the PDF inhibitor in the absence of tetracycline.
Growth inhibition (the half-maximal growth rate) could already be
detected at a concentration of 0.5 to 0.6 µM. The addition of
tetracycline (20 ng/ml) shifted the 50% inhibitory concentration to a
slightly higher concentration (1.2 µM).

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 5.
Effect of reduced PDF expression on growth inhibition by
Ro 66-6976 in S. pneumoniae. Strains R6 and KO3 were grown
to an OD620 of 0.05 and distributed into 96-well plates.
Increasing amounts of the inhibitor Ro 66-6976 with or without 20 ng of
tetracycline (tet)/ml were added. The OD595 was measured
after 16 h of incubation. One representative experiment is shown.
wt, wild type.
|
|
Analysis of changes in protein pattern caused by treatment of
H. influenzae Rd KW 20 with PDF inhibitors.
Mid-log-phase cultures of H. influenzae Rd KW 20 were
treated with subinhibitory concentrations of the PDF inhibitor
actinonin (Ro 06-1467) for 90 min and pulse-labeled for 5 min
with L-[35S]methionine. Extracts were
prepared, and the proteins were resolved by 2D PAGE. The protein
patterns detected were compared to those obtained from an untreated
pulse-labeled control culture. An overlay of the two images revealed
that numerous spot shifts, directed towards the anode, were caused by
treatment with the inhibitor. This indicates a decrease in the
isoelectric points of the shifted proteins (Fig.
6). Little change was observed for the
high-molecular-weight proteins, while the pIs of the majority of the
low-molecular-weight proteins were changed. As a protein map of
H. influenzae Rd KW 20 was available (17), the
differences in pI with and without PDF inhibitor treatment could be
estimated for some proteins and compared to the calculated values. In
all cases examined, the pI difference was in good agreement with the
assumption that the shifts are due to the formyl groups that are not
removed and that block the N-terminal amino group (Table
1). Experiments carried out with compound
Ro 66-0376 yielded results identical to those obtained with actinonin.
Studies using S. pneumoniae as a gram-positive model
organism also revealed spot shifts towards a more acidic pI (data not
shown). Of note, 2D PAGE analysis of unlabeled protein extracts from
long-term-treated bacterial cultures followed by Coomassie staining did
not detect spot shifts (data not shown), which indicates that the
residual PDF activity remaining after treatment with subinhibitory
concentrations of the inhibitors suffices for the near-complete
deformylation of the newly synthesized proteins. The effect of the
inhibitors visualized with pulse-labeled cultures, therefore,
corresponds to a delay rather than to a complete block of
deformylation.

View larger version (69K):
[in this window]
[in a new window]
|
FIG. 6.
Isoelectric point shifts in proteins triggered by
treatment with inhibitors of PDF. in H. influenzae as
visualized by 2D PAGE of pulse-labeled protein extracts. Only sections
of the 2D gels are shown. (A) Control culture without of addition of
inhibitor. The red circles indicate spots that were shifted after the
addition of deformylase inhibitors. The spots for which a detailed
analysis of the amplitude of the shifts was undertaken are labeled. (B)
Culture treated with 16 µg of Ro 06-1467/ml for 90 min. The red
circles indicate the positions of spots without treatment. The lines
illustrate the spot shifts.
|
|
Antibacterial activity of inhibitors of PDF is reversed by
trimethoprim in rich medium.
The antibiotic trimethoprim inhibits
dihydrofolate reductase and thereby promotes the depletion of the
tetrahydrofolate pool. Mazel et al. showed that E. coli with
an inactivated pdf gene can grow slowly in a rich medium
containing trimethoprim and thymidine, supposedly using unformylated
Met-tRNA, which results in slow growth independent of the action of
deformylase (20). This artificial condition mimics a
mutation in the fmt gene. Under such conditions, a specific
PDF inhibitor should not inhibit bacterial growth. This was indeed
observed with Ro 66-0376 and Ro 66-6976 in medium supplied with
trimethoprim and thymidine (Table 2).
Antibacterial activity is bacteriostatic.
PDF inhibitors
inhibited the growth of E. coli DC2 in a bacteriostatic
manner and are not bactericidal. This is comparable to the action of
erythromycin (Fig. 7).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 7.
Time-kill kinetics with E. coli DC2. The
effect of the addition of Ro 66-0376 (32 µg/ml; solid squares)
compared to that of erythromycin (32 µg/ml; solid triangles) on CFU
is shown. Open circles, untreated control.
|
|
Development of in vitro resistance to Ro 66-6976 and analysis of
resistant mutants.
Mutants resistant to Ro 66-6976 were selected
by plating E. coli XL2-blue on agar containing 64 µg of Ro
66-6976/ml. Resistant colonies appeared after 3 days at a frequency of
10
7. All isolated mutants exhibited lower growth rates
than the wild-type strain, i.e., doubling times of 1.2 to 2 h
compared to 0.4 h in the wild type (data not shown). The two
selected mutants were completely resistant to both inhibitors, Ro
66-0376 and Ro 66-6796, whereas their susceptibilities to unrelated
antibiotics were not significantly altered (Table
3). The fmt-pdf operons of
both mutants were sequenced, and a Tn10 insertion in the
fmt gene was found in both cases.
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Susceptibilities of spontaneous Ro 66-6976-resistant
mutants compared to that of the E. coli wild-type strain for
two PDF inhibitors and two unrelated antibiotics
|
|
 |
DISCUSSION |
In the accompanying paper, we demonstrated that the PDF inhibitors
recently synthesized by our group show activity in E. coli cell homogenates and intact cells. In this report, the following questions are addressed: (i) do the compounds exert their antibacterial action by targeting PDF, (ii) do they lead to impaired deformylation of
multiple intracellular proteins in species other than E. coli, and (iii) at what rate does the development of resistance occur?
Regulation of the level of expression of the target enzyme is one
approach to demonstrate that the antibacterial activity of the PDF
inhibitors is really related to inhibition of deformylase activity and
is not caused by the inhibition of an unrelated target. Using this
approach, Chen et al. have successfully demonstrated that actinonin, a
naturally occurring antibacterial agent, acts by inhibiting PDF in
E. coli (11). Using similar methodology, we
cloned the pdf genes from several bacterial strains
(E. coli, S. pneumoniae, and H. influenzae) into vectors
that allow the regulation of their expression by varying the IPTG
concentration. For the E. coli and S. pneumoniae
enzymes, it could be clearly shown that the susceptibility to PDF
inhibitors decreases with increasing levels of expression of
pdf. Overexpression of the H. influenzae enzyme
also had this effect, but to a lesser degree. Conversely, decreasing
levels of pdf expression in S. pneumoniae resulted in an increased susceptibility to the inhibitors. Taken together, these experiments strongly suggest that the compounds tested
inhibit bacterial-cell growth by targeting PDF.
We analyzed the protein extracts from pulse-labeled PDF
inhibitor-treated and untreated bacterial cultures by 2D PAGE. In gram-positive and gram-negative model organisms it was shown that treatment with PDF inhibitors leads to multiple spot shifts that are
most likely due to the blocking of PDF activity, which again argues
strongly in favor of the proposed mode of action. This effect was seen
in a multitude of spots. Finally, the observations that impaired
methionyl-tRNAMet formylation triggered by trimethoprim
treatment antagonizes the action of the PDF inhibitors and that
resistant mutants carry a mutation in the fmt gene are
further pieces of evidence indicating that PDF inhibition is
responsible for the antibacterial action of the hydroxamic acid
derivatives tested.
If Coomassie staining was used for protein visualization in the 2D PAGE
experiments, no spot shifts could be seen even after prolonged
incubation with the inhibitors. Together with the observation that the
low level of pdf expression in the regulatable S. pneumoniae knockout strains did not impair their viability, this
indicates that a low level of PDF activity in the cells suffices to
sustain growth. However, the observation that no mutants with a totally inactivated pdf gene could be obtained in S. pneumoniae strongly suggests that the enzyme is essential in this
organism, although the results presented cannot exclude polar effects.
The compounds tested were bacteriostatic, and rapid development of
resistance occurred in E. coli. Although bacteriostatic action has also been described for actinonin (11), this
may not be a general characteristic of PDF inhibitors, as a series of
peptide thiols described recently (15) show bactericidal activity. However, this was only convincingly demonstrated in Bacillus subtilis, which may be particularly susceptible to
this class of compounds. The same authors also did not observe any development of resistance in B. subtilis, suggesting that
rapid development of resistance may not be a general property of PDF inhibitors.
Sequence alignments from public data banks show that the pdf
gene is ubiquitous in the bacterial domain, and the essential residues
are highly conserved. In some bacteria, such as S. pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, B. subtilis,
Enterococcus faecalis, and Vibrio cholerae, two
pdf-like sequences can be detected by sequence similarity
searching. The roles of the two individual genes are as yet unclear.
However, their presence raises the possibility that resistance in these
organisms may arise through a bypass mechanism. Moreover, a partial
sequence with similarity to an internal part of pdf was
identified in a proprietary data bank of human DNA sequences. So far,
our attempts to express functionally active human protein have been
unsuccessful. It can be speculated that the protein encoded by this
gene is active in the mitochondria, as mitochondrial protein synthesis
is initiated by methionyl-tRNA
(9) and
no pdf gene has been detected in this organelle. This may be
an argument against the concept that PDF activity is not required in eukaryotes.
The existence of multiple pdf-like genes in some bacterial
species and the possibility of the existence of a human homologue shed
some doubt on the value of PDF as a target for broad-spectrum antibacterial drugs. Furthermore, the questions of the development of
resistance and bactericidal or bacteriostatic action in different bacterial species and by different chemical classes of inhibitors need
to be more broadly addressed to fully validate PDF as an antibacterial target.
 |
ACKNOWLEDGMENTS |
We acknowledge the expert technical assistance of Karin Di
Padova, Christian Lacoste, Olivier Partouche, Bernadette Prud'hon, and
Bernard Rutten.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: F. Hoffmann-La
Roche Ltd., PRBM-H, Bldg. 69/11A, CH-4070 Basel, Switzerland. Phone: 41 61 688 5878. Fax: 41 61 688 2377. E-mail:
christian.apfel{at}roche.com.
Present address: Morphochem AG, Basel, Switzerland.
 |
REFERENCES |
| 1.
|
Adams, J. M.
1968.
On the release of the formyl group from nascent protein.
J. Mol. Biol.
33:571-589[CrossRef][Medline].
|
| 2.
|
Alloing, G.,
P. de Philip, and J. P. Claverys.
1994.
Three highly homologous membrane-bound lipoproteins participate in oligopeptide transport by the Ami system of the gram-positive Streptococcus pneumoniae.
J. Mol. Biol.
241:44-58[CrossRef][Medline].
|
| 3.
|
Apfel, C.,
D. W. Banner,
D. Bur,
M. Dietz,
T. Hirata,
C. Hubschwerlen,
H. Locher,
M. G. Page,
W. Pirson,
G. Rosse, and J. L. Specklin.
2000.
Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.
J. Med. Chem.
43:2324-2331[CrossRef][Medline].
|
| 4.
|
Apfel, C. M.,
B. Takacs,
M. Fountoulakis,
M. Stieger, and W. Keck.
1999.
Use of genomics to identify bacterial undecaprenyl pyrosphosphate synthetase: cloning, expression, and characterization of the essential uppS gene.
J. Bacteriol.
181:483-492[Abstract/Free Full Text].
|
| 4a.
|
Apfel, C. M.,
S. Evers,
C. Hubschwerlen,
W. Pirson,
M. G. P. Page, and W. Keck.
2001.
Peptide deformylase as an antibacterial drug target: assays for detection of its inhibition in Escherichia coli cell homogenates and intact cells.
Antimicrob. Agents Chemother.
45:1053-1057[Abstract/Free Full Text].
|
| 5.
|
Ausubel, F. M.,
R. Brent,
R. E. Kingston,
D. D. Moore,
J. G. Seidman,
J. A. Smith, and K. Struhl.
1997.
Current protocols in molecular biology.
Wiley Interscience, New York, N.Y.
|
| 6.
|
Avery, O. T.,
C. M. MacLeod, and M. McCarty.
1944.
Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Induction of transformation by a desoxyribonucleic acid fraction isolated from Pneumococcus type III.
J. Exp. Med.
79:137-158[Abstract].
|
| 7.
|
Ball, L. A., and P. Kaesberg.
1973.
Cleavage of the N-terminal formylmethionine residue from a bacteriophage coat protein in vitro.
J. Mol. Biol.
79:531-537[CrossRef][Medline].
|
| 8.
|
Barcak, G. J.,
M. S. Chandler,
R. J. Redfield, and J. F. Tomb.
1991.
Genetic systems in Haemophilus influenzae.
Methods Enzymol.
204:321-342[Medline].
|
| 9.
|
Bianchetti, R.,
G. Lucchini,
P. Crosti, and P. Tortora.
1977.
Dependence of mitochondrial protein synthesis initiation on formylation of the initiator methionyl-tRNAf.
J. Biol. Chem.
252:2519-2523[Abstract/Free Full Text].
|
| 10.
|
Chang, S. Y.,
E. C. McGary, and S. Chang.
1989.
Methionine aminopeptidase gene of Escherichia coli is essential for cell growth.
J. Bacteriol.
171:4071-4072[Abstract/Free Full Text].
|
| 11.
|
Chen, D. Z.,
D. V. Patel,
C. J. Hackbarth,
W. Wang,
G. Dreyer,
D. C. Young,
P. S. Margolis,
C. Wu,
Z. J. Ni,
J. Trias,
R. J. White, and Z. Yuan.
2000.
Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor.
Biochemistry
39:1256-1262[CrossRef][Medline].
|
| 12.
|
Chen, J. D., and D. A. Morrison.
1988.
Construction and properties of a new insertion vector, pJDC9, that is protected by transcriptional terminators and useful for cloning of DNA from Streptococcus pneumoniae.
Gene
64:155-164[CrossRef][Medline].
|
| 13.
|
Devereux, J.,
P. Haeberli, and O. Smithies.
1984.
A comprehensive set of sequence analysis programs for the VAX.
Nucleic Acids Res.
12:387-395.
|
| 14.
|
Havarstein, L. S.,
G. Coomaraswamy, and D. A. Morrison.
1995.
An unmodified heptadecapeptide pheromone induces competence for genetic transformation in Streptococcus pneumoniae.
Proc. Natl. Acad. Sci. USA
92:11140-11144[Abstract/Free Full Text].
|
| 15.
|
Huntington, K. M.,
T. Yi,
Y. Wei, and D. Pei.
2000.
Synthesis and antibacterial activity of peptide deformylase inhibitors.
Biochemistry
39:4543-4551[CrossRef][Medline].
|
| 16.
|
Lacks, S.
1966.
Integration efficiency and genetic recombination in pneumococcal transformation.
Genetics
53:207-235[Free Full Text].
|
| 17.
|
Langen, H.,
B. Takacs,
S. Evers,
P. Berndt,
H. W. Lahm,
B. Wipf,
C. Gray, and M. Fountoulakis.
2000.
Two-dimensional map of the proteome of Haemophilus influenzae.
Electrophoresis
21:411-429[CrossRef][Medline].
|
| 18.
|
Lutz, R., and H. Bujard.
1997.
Independent and tight regulation of transcriptional units in Escherichia coli via the LacR/O, the TetR/O and AraC/I1-I2 regulatory elements.
Nucleic Acids Res.
25:1203-1210[Abstract/Free Full Text].
|
| 19.
|
Marcker, K., and F. Sanger.
1963.
N-Formyl-methionyl-tRNA.
J. Mol. Biol.
8:835-840.
|
| 20.
|
Mazel, D.,
S. Pochet, and P. Marliere.
1994.
Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation.
EMBO J.
13:914-923[Medline].
|
| 21.
|
Meinnel, T., and S. Blanquet.
1994.
Characterization of the Thermus thermophilus locus encoding peptide deformylase and methionyl-tRNA(fMet) formyltransferase.
J. Bacteriol.
176:7387-7390[Abstract/Free Full Text].
|
| 22.
|
Meinnel, T.,
Y. Mechulam, and S. Blanquet.
1993.
Methionine as translation start signal: a review of the enzymes of the pathway in Escherichia coli.
Biochimie
75:1061-1075[Medline].
|
| 23.
|
Pozzi, G.,
M. R. Oggioni,
R. Manganelli, and R. Plevani.
1991.
Genetic manipulation of streptococci by chromosomal integration of recombinant DNA, p. 59-61.
In
G. M. Dunny, P. P. Cleary, and L. L. McKay (ed.), Genetics and molecular biology of streptococci, lactococci, and enterococci. American Society for Microbiology, Washington, D.C.
|
| 24.
|
Sambrook, J.,
E. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 25.
|
Sanchez, J.,
R. Appel,
O. Golaz,
C. Pasquali,
F. Ravier,
A. Bairoch, and D. Hochstrasser.
1995.
Inside SWISS 2DPAGE database.
Electrophoresis
16:1131-1151[CrossRef][Medline].
|
| 26.
|
Sanger, F.,
S. Nicklen, and A. Coulson.
1977.
DNA sequencing with chain-terminating inhibitors.
Proc. Natl. Acad. Sci. USA
74:5463-5467[Abstract/Free Full Text].
|
| 27.
|
Solbiati, J.,
A. Chapman-Smith,
J. L. Miller,
C. G. Miller, and J. E. Cronan, Jr.
1999.
Processing of the N termini of nascent polypeptide chains requires deformylation prior to methionine removal.
J. Mol. Biol.
290:607-614[CrossRef][Medline].
|
| 28.
|
Stieger, M.,
B. Wohlgensinger,
M. Kamber,
L. Rolf, and W. Keck.
1999.
Integrational plasmids for the tetracycline-regulated expression of genes in Streptococcus pneumoniae.
Gene
226:243-251[CrossRef][Medline].
|
| 29.
|
Studier, F. W., and B. A. Moffatt.
1986.
Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes.
J. Mol. Biol.
189:113-130[CrossRef][Medline].
|
Antimicrobial Agents and Chemotherapy, April 2001, p. 1058-1064, Vol. 45, No. 4
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.4.1058-1064.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Caughlan, R. E., Sriram, S., Daigle, D. M., Woods, A. L., Buco, J., Peterson, R. L., Dzink-Fox, J., Walker, S., Dean, C. R.
(2009). Fmt Bypass in Pseudomonas aeruginosa Causes Induction of MexXY Efflux Pump Expression. Antimicrob. Agents Chemother.
53: 5015-5021
[Abstract]
[Full Text]
-
Duroc, Y., Giglione, C., Meinnel, T.
(2009). Mutations in Three Distinct Loci Cause Resistance to Peptide Deformylase Inhibitors in Bacillus subtilis. Antimicrob. Agents Chemother.
53: 1673-1678
[Abstract]
[Full Text]
-
Biswas, I., Jha, J. K., Fromm, N.
(2008). Shuttle expression plasmids for genetic studies in Streptococcus mutans. Microbiology
154: 2275-2282
[Abstract]
[Full Text]
-
Dean, C. R., Narayan, S., Richards, J., Daigle, D. M., Esterow, S., Leeds, J. A., Kamp, H., Puyang, X., Wiedmann, B., Mueller, D., Voshol, H., van Oostrum, J., Wall, D., Koehn, J., Dzink-Fox, J., Ryder, N. S.
(2007). Reduced Susceptibility of Haemophilus influenzae to the Peptide Deformylase Inhibitor LBM415 Can Result from Target Protein Overexpression Due to Amplified Chromosomal def Gene Copy Number. Antimicrob. Agents Chemother.
51: 1004-1010
[Abstract]
[Full Text]
-
Liebscher, M., Jahreis, G., Lucke, C., Grabley, S., Raina, S., Schiene-Fischer, C.
(2007). Fatty Acyl Benzamido Antibacterials Based on Inhibition of DnaK-catalyzed Protein Folding. J. Biol. Chem.
282: 4437-4446
[Abstract]
[Full Text]
-
Teo, J. W. P., Thayalan, P., Beer, D., Yap, A. S. L., Nanjundappa, M., Ngew, X., Duraiswamy, J., Liung, S., Dartois, V., Schreiber, M., Hasan, S., Cynamon, M., Ryder, N. S., Yang, X., Weidmann, B., Bracken, K., Dick, T., Mukherjee, K.
(2006). Peptide Deformylase Inhibitors as Potent Antimycobacterial Agents. Antimicrob. Agents Chemother.
50: 3665-3673
[Abstract]
[Full Text]
-
Nilsson, A. I., Zorzet, A., Kanth, A., Dahlstrom, S., Berg, O. G., Andersson, D. I.
(2006). Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes. Proc. Natl. Acad. Sci. USA
103: 6976-6981
[Abstract]
[Full Text]
-
Wang, W., White, R., Yuan, Z.
(2006). Proteomic Study of Peptide Deformylase Inhibition in Streptococcus pneumoniae and Staphylococcus aureus.. Antimicrob. Agents Chemother.
50: 1656-1663
[Abstract]
[Full Text]
-
Saxena, R., Chakraborti, P. K.
(2005). Identification of Regions Involved in Enzymatic Stability of Peptide Deformylase of Mycobacterium tuberculosis. J. Bacteriol.
187: 8216-8220
[Abstract]
[Full Text]
-
Fonseca-Aten, M., Salvatore, C. M., Mejias, A., Rios, A. M., Chavez-Bueno, S., Katz, K., Gomez, A. M., McCracken, G. H. Jr, Hardy, R. D.
(2005). Evaluation of LBM415 (NVP PDF-713), a Novel Peptide Deformylase Inhibitor, for Treatment of Experimental Mycoplasma pneumoniae Pneumonia. Antimicrob. Agents Chemother.
49: 4128-4136
[Abstract]
[Full Text]
-
Dean, C. R., Narayan, S., Daigle, D. M., Dzink-Fox, J. L., Puyang, X., Bracken, K. R., Dean, K. E., Weidmann, B., Yuan, Z., Jain, R., Ryder, N. S.
(2005). Role of the AcrAB-TolC Efflux Pump in Determining Susceptibility of Haemophilus influenzae to the Novel Peptide Deformylase Inhibitor LBM415. Antimicrob. Agents Chemother.
49: 3129-3135
[Abstract]
[Full Text]
-
Waites, K. B., Reddy, N. B., Crabb, D. M., Duffy, L. B.
(2005). Comparative In Vitro Activities of Investigational Peptide Deformylase Inhibitor NVP LBM-415 and Other Agents against Human Mycoplasmas and Ureaplasmas. Antimicrob. Agents Chemother.
49: 2541-2542
[Abstract]
[Full Text]
-
Fritsche, T. R., Sader, H. S., Cleeland, R., Jones, R. N.
(2005). Comparative Antimicrobial Characterization of LBM415 (NVP PDF-713), a New Peptide Deformylase Inhibitor of Clinical Importance. Antimicrob. Agents Chemother.
49: 1468-1476
[Abstract]
[Full Text]
-
Bell, J. M., Turnidge, J. D., Inoue, M., Kohno, S., Hirakata, Y., Ono, Y., Jones, R. N.
(2005). Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan. J Antimicrob Chemother
55: 276-278
[Full Text]
-
Hutter, B., Fischer, C., Jacobi, A., Schaab, C., Loferer, H.
(2004). Panel of Bacillus subtilis Reporter Strains Indicative of Various Modes of Action. Antimicrob. Agents Chemother.
48: 2588-2594
[Abstract]
[Full Text]
-
Jones, R. N., Moet, G. J., Sader, H. S., Fritsche, T. R.
(2004). Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates. J Antimicrob Chemother
53: 804-807
[Abstract]
[Full Text]
-
Cynamon, M. H., Alvirez-Freites, E., Yeo, A. E. T.
(2004). BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis. J Antimicrob Chemother
53: 403-405
[Full Text]
-
Chan, P. F., O'Dwyer, K. M., Palmer, L. M., Ambrad, J. D., Ingraham, K. A., So, C., Lonetto, M. A., Biswas, S., Rosenberg, M., Holmes, D. J., Zalacain, M.
(2003). Characterization of a Novel Fucose-Regulated Promoter (PfcsK) Suitable for Gene Essentiality and Antibacterial Mode-of-Action Studies in Streptococcus pneumoniae. J. Bacteriol.
185: 2051-2058
[Abstract]
[Full Text]
-
Jones, R. N., Rhomberg, P. R.
(2003). Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. J Antimicrob Chemother
51: 157-161
[Abstract]
[Full Text]
-
Hackbarth, C. J., Chen, D. Z., Lewis, J. G., Clark, K., Mangold, J. B., Cramer, J. A., Margolis, P. S., Wang, W., Koehn, J., Wu, C., Lopez, S., Withers, G. III, Gu, H., Dunn, E., Kulathila, R., Pan, S.-H., Porter, W. L., Jacobs, J., Trias, J., Patel, D. V., Weidmann, B., White, R. J., Yuan, Z.
(2002). N-Alkyl Urea Hydroxamic Acids as a New Class of Peptide Deformylase Inhibitors with Antibacterial Activity. Antimicrob. Agents Chemother.
46: 2752-2764
[Abstract]
[Full Text]
-
Apfel, C. M., Evers, S., Hubschwerlen, C., Pirson, W., Page, M. G. P., Keck, W.
(2001). Peptide Deformylase as an Antibacterial Drug Target: Assays for Detection of Its Inhibition in Escherichia coli Cell Homogenates and Intact Cells. Antimicrob. Agents Chemother.
45: 1053-1057
[Abstract]
[Full Text]